BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lisaftoclax readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lisaftoclax\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05147467-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT05147467)
DESCRIPTION:Lisaftoclax\, phase 2\, Relapsed/Refractory Chronic Lymphocytic
  Leukemia.\nStudy: Study of APG-2575 in Patients With Relapsed/Refractory 
 CLL/SLL\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05147467
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05495035-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lisaftoclax: Phase 1 readout est. (NCT05495035)
DESCRIPTION:Lisaftoclax\, phase 1.\nStudy: Study for Safety and Efficacy of
  Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractor
 y Ph + ALL\nEstimated primary completion: 31 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05495035
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06104566-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT06104566)
DESCRIPTION:Lisaftoclax\, phase 3.\nStudy: Global Trial in APG2575 for Pati
 ents With CLL/SLL\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06104566
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06401603-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Lisaftoclax: Phase 1 readout est. (NCT06401603)
DESCRIPTION:Lisaftoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase
  I Study of Decitabine\, Lisaftoclax\, and Olverembatinib in Patients With
  Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Ac
 ute Myeloid Leukemia\nEstimated primary completion: 1 January 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06401603
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07552324-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT07552324)
DESCRIPTION:Lisaftoclax\, phase 2.\nStudy: Study on the Treatment of Double
 /Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-
 R-CHP\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07552324
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05701306-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Lisaftoclax: Phase 1/2 readout est. (NCT05701306)
DESCRIPTION:Lisaftoclax\, phase 1/2.\nStudy: APG-115 Alone or in Combinatio
 n With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors\n
 Estimated primary completion: 1 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05701306
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459608-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT07459608)
DESCRIPTION:Lisaftoclax\, phase 2.\nStudy: Efficacy and Safety of Lisaftocl
 ax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma\nEstimat
 ed primary completion: 1 July 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07459608
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06319456-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT06319456)
DESCRIPTION:Lisaftoclax\, phase 3.\nStudy: A Study of Lisaftoclax (APG-2575
 ) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnose
 d CLL/SLL.\nEstimated primary completion: August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06319456
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07813390-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT07813390)
DESCRIPTION:Lisaftoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Homohar
 ringtonine\, Lisaftoclax\, and Azacitidine for AML After Venetoclax-Based 
 Therapy Failure\nEstimated primary completion: 1 September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07813390
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265545-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Lisaftoclax: Phase na readout est. (NCT06265545)
DESCRIPTION:Lisaftoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: Multic
 enter\, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid
  Leukemia\nEstimated primary completion: 30 January 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06265545
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505160-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT07505160)
DESCRIPTION:Lisaftoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Efficac
 y and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Vene
 toclax/Azacitidine Pretreated AML Patients\nEstimated primary completion: 
 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lisaftocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7505160
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389292-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20280525
DTEND;VALUE=DATE:20280526
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT06389292)
DESCRIPTION:Lisaftoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Pivot
 al Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatm
 ent of Acute Myeloid Leukemia\nEstimated primary completion: 25 May 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06389292
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601607-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Lisaftoclax: Phase 1/2 readout est. (NCT07601607)
DESCRIPTION:Lisaftoclax\, phase 1/2.\nStudy: Lisaftoclax Plus Chidamide and
  Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma\nEstima
 ted primary completion: 30 May 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07601607
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07597941-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Lisaftoclax: Phase 2/3 readout est. (NCT07597941)
DESCRIPTION:Lisaftoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Lisaf
 toclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Le
 ukemia Patients\nEstimated primary completion: June 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07597941
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04501120-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Lisaftoclax: Phase 1/2 readout est. (NCT04501120)
DESCRIPTION:Lisaftoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Pa
 tients Relapsed/Refractory AML\nEstimated primary completion: September 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04501120
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07272499-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20280910
DTEND;VALUE=DATE:20280911
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT07272499)
DESCRIPTION:Lisaftoclax\, phase 2.\nStudy: Orelabrutinib Plus Lisaftoclax a
 nd Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease\nEst
 imated primary completion: 10 September 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07272499
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255963-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT07255963)
DESCRIPTION:Lisaftoclax\, phase 2.\nStudy: Pirtobrutinib\, Lisaftoclax\, an
 d Rituximab in the Treatment of R/R DLBCL\nEstimated primary completion: 3
 0 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lis
 aftoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07255963
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684950-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT07684950)
DESCRIPTION:Lisaftoclax\, phase 2.\nStudy: Lisaftoclax Plus Pirtobrutinib i
 n Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy\n
 Estimated primary completion: 30 October 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07684950
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717580-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT07717580)
DESCRIPTION:Lisaftoclax\, phase 2.\nStudy: Efficacy and Safety of Brentuxim
 ab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (C
 TCL)\nEstimated primary completion: 30 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07717580
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398638-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Lisaftoclax: Phase 1/2 readout est. (NCT07398638)
DESCRIPTION:Lisaftoclax\, phase 1/2.\nStudy: Lisatoclax Plus R-CHOP or Pola
 -R-CHP in Untreated DLBCL: A Phase Ib/II Study\nEstimated primary completi
 on: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /lisaftoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07398638
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06641414-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT06641414)
DESCRIPTION:Lisaftoclax\, phase 3.\nStudy: Lisaftoclax (APG-2575) Combined 
 With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelo
 dysplastic Syndrome (GLORA-4).\nEstimated primary completion: June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06641414
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07795099-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Lisaftoclax: Phase na readout est. (NCT07795099)
DESCRIPTION:Lisaftoclax\, phase na.\nStudy: A Single-center\, Prospective\,
  Exploratory Clinical Study\nEstimated primary completion: August 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07795099
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07651163-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lisaftoclax: Phase 2/3 readout est. (NCT07651163)
DESCRIPTION:Lisaftoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Compa
 ring the Efficacy of LDA\, LHAA\, and LA Regimens in Young Adults With Int
 ermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Che
 motherapy\nEstimated primary completion: December 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07651163
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07651176-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lisaftoclax: Phase 2/3 readout est. (NCT07651176)
DESCRIPTION:Lisaftoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Compa
 ring the Efficacy of the LDA\, LHAA\, and DA Regimens in Young Adults With
  Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy\nEsti
 mated primary completion: December 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07651176
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686965-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20300810
DTEND;VALUE=DATE:20300811
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT07686965)
DESCRIPTION:Lisaftoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Lisafto
 clax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell
  Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relaps
 e\nEstimated primary completion: 10 August 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07686965
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07831395-2883@assetmemo.bio
DTSTAMP:20261121T004117Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT07831395)
DESCRIPTION:Lisaftoclax\, phase 2.\nStudy: Rituximab\, Pirtobrutinib\, Lisa
 ftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed Fr
 om CLL\nEstimated primary completion: 31 December 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07831395
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
